 |
22 Products |  |
94 Diseases | | 22 Products |
|
46 Trials |  |
2720 News |  |
| «12...15161718192021222324252627» |
- ||||| Aplidin (plitidepsin) / PharmaMar, Roche
Enrollment closed, Trial primary completion date, Combination therapy: ADMYRE: Aplidin - Dexamethasone in Relapsed/Refractory Myeloma (clinicaltrials.gov) - Jun 12, 2015
P3, N=250, Active, not recruiting, Sponsor: PharmaMar
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015
- || Kanarb (fimasartan) - Boryung Group, R / Pharm
New P3 trial: FIRME-1: Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension (clinicaltrials.gov) - Jun 9, 2015
P3, N=272, Completed, Sponsor: Stendhal Americas, S.A.
- |||||||||| DTaP-IPV combination vaccine / Boryung Group
New P3 trial: Venus: Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS (clinicaltrials.gov) - Jun 1, 2015
P3, N=464, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Metastases: PM1183-B-005-14: Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors (clinicaltrials.gov) - May 27, 2015
P2, N=225, Not yet recruiting, Sponsor: PharmaMar
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors (clinicaltrials.gov) - May 21, 2015
P1, N=25, Not yet recruiting, Sponsor: PharmaMar
- |||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open: CORAIL: Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (clinicaltrials.gov) - May 20, 2015
P3, N=420, Recruiting, Sponsor: PharmaMar
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Combination therapy, Metastases: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas (clinicaltrials.gov) - May 19, 2015
P2, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial initiation date, Trial primary completion date, BRCA Biomarker, Metastases: A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer (clinicaltrials.gov) - Apr 28, 2015
P2, N=117, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Initiation date: Jun 2012 --> Dec 2012 | Trial primary completion date: Mar 2015 --> Jun 2017
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P3 trial: CORAIL: Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (clinicaltrials.gov) - Apr 20, 2015
P3, N=420, Not yet recruiting, Sponsor: PharmaMar
- ||||| Kanarb (fimasartan) - Boryung Group, R / Pharm
Enrollment closed, Enrollment open, Trial primary completion date: Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar (clinicaltrials.gov) - Apr 6, 2015
P3, N=176, Active, not recruiting, Sponsor: R-Pharm
Initiation date: Jun 2012 --> Dec 2012 | Trial primary completion date: Mar 2015 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2015
- ||||| Kanarb (fimasartan) - Boryung Group, R / Pharm
New P4 trial: FAVOR: Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol (clinicaltrials.gov) - Mar 31, 2015
P4, N=105, Active, not recruiting, Sponsor: Ajou University School of Medicine
- | Kanarb (fimasartan) - Boryung Group, R / Pharm
New P1 trial: Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers (clinicaltrials.gov) - Mar 25, 2015
P1, N=36, Not yet recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- | Dukaro (amlodipine/fimasartan/rosuvastatin) / Boryung Group
New P1 trial: Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects (clinicaltrials.gov) - Mar 25, 2015
P1, N=50, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- ||| Kanarb (fimasartan) - Boryung Group, R / Pharm
Clinical: K-HEMS: Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study) (clinicaltrials.gov) - Mar 20, 2015
P=N/A, N=14000, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- ||| Kanarb (fimasartan) - Boryung Group, R / Pharm
Clinical: Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=400, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- Aplidin (plitidepsin) / PharmaMar, Roche
Trial primary completion date, Metastases: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial (clinicaltrials.gov) - Mar 5, 2015
P2, N=24, Terminated, Sponsor: Institut Bergoni
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2015 Trial primary completion date: Dec 2013 --> Dec 2015
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment closed, Trial primary completion date, Metastases: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 10, 2015
P1, N=50, Active, not recruiting, Sponsor: PharmaMar
Trial primary completion date: Dec 2013 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016
- ||| Kanarb (fimasartan) - Boryung Group, R / Pharm
Enrollment change: FINE: A Trial of Fimasartan for Early Diastolic Heart Failure (clinicaltrials.gov) - Jan 13, 2015
P4, N=60, Recruiting, Sponsor: Asan Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016 N=128 --> 60
- ||| Kanarb (fimasartan) - Boryung Group, R / Pharm
Clinical: Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=56, Recruiting, Sponsor: Seoul National University Hospital
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date: Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks (clinicaltrials.gov) - Oct 28, 2014
P1, N=42, Recruiting, Sponsor: PharmaMar
N=128 --> 60 Trial primary completion date: Nov 2013 --> Nov 2015
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date, Metastases: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 28, 2014
P1, N=50, Recruiting, Sponsor: PharmaMar
Trial primary completion date: Nov 2013 --> Nov 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- BR2001 / Boryung Group
Trial primary completion date: LAL-BR/2001: Study Treatment to Low Risk ALL (clinicaltrials.gov) - Oct 28, 2014
P4, N=150, Recruiting, Sponsor: PETHEMA Foundation
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Apr 2014 --> Apr 2015
- Aplidin (plitidepsin) / PharmaMar, Roche
Enrollment open, Combination therapy: Study of Plitidepsin (Aplidin (clinicaltrials.gov) - Oct 28, 2014
P1, N=25, Recruiting, Sponsor: PharmaMar
Trial primary completion date: Apr 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Combination therapy, Metastases: Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors (clinicaltrials.gov) - Oct 28, 2014
P1, N=50, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date, Combination therapy, Metastases: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (clinicaltrials.gov) - Oct 22, 2014
P1, N=73, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- Kanarb (fimasartan) - Boryung Group, R / Pharm
Enrollment open, Combination therapy: A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide (clinicaltrials.gov) - Oct 17, 2014
P2, N=0, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
Trial primary completion date: Jun 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- ||| Tuvero (fimasartan/rosuvastatin) / Boryung Group
Trial completion: to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin (clinicaltrials.gov) - Oct 17, 2014
P1, N=81, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Combination therapy: A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Oct 15, 2014
P2, N=120, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Kanarb (fimasartan) - Boryung Group, R / Pharm
New P3 trial: Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar (clinicaltrials.gov) - Sep 28, 2014
P3, N=176, Recruiting, Sponsor: R-Pharm
- |||| Kanarb (fimasartan) - Boryung Group, R / Pharm
Trial completion: A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension (clinicaltrials.gov) - Sep 8, 2014
P2, N=75, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed
- Kanarb (fimasartan) - Boryung Group, R / Pharm
New P2 trial, Combination therapy: A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide (clinicaltrials.gov) - Aug 21, 2014
P2, N=0, Not yet recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). (clinicaltrials.gov) - Aug 6, 2014
P1, N=40, Recruiting, Sponsor: PharmaMar
- ||| Tuvero (fimasartan/rosuvastatin) / Boryung Group
New P1 trial: to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin (clinicaltrials.gov) - Aug 1, 2014
P1, N=80, Not yet recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- |||| Aplidin (plitidepsin) / PharmaMar, Roche
Trial primary completion date, Combination therapy: ADMYRE: Aplidin - Dexamethasone in Relapsed/Refractory Myeloma (clinicaltrials.gov) - Jul 8, 2014
P3, N=250, Recruiting, Sponsor: PharmaMar
Recruiting --> Completed Trial primary completion date: Jun 2014 --> Dec 2014
- |||||||||| Tuvero (fimasartan/rosuvastatin) / Boryung Group
New P3 trial: A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia (clinicaltrials.gov) - Jun 19, 2014
P3, N=135, Not yet recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- | Kanarb (fimasartan) - Boryung Group, R / Pharm
New P4 trial: Effect of High- and Low-sodium Intake on the Pharmacokinetics and Pharmacodynamic Effects of Fimasartan (clinicaltrials.gov) - May 26, 2014
P4, N=16, Recruiting, Sponsor: DongGuk University
- || Kanarb (fimasartan) - Boryung Group, R / Pharm
Trial primary completion date: FINE: A Trial of Fimasartan for Early Diastolic Heart Failure (clinicaltrials.gov) - May 19, 2014
P4, N=128, Recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Jun 2014 --> Dec 2014 Trial primary completion date: Sep 2014 --> Apr 2015
- || Kanarb (fimasartan) - Boryung Group, R / Pharm
Trial completion date: FINE: A Trial of Fimasartan for Early Diastolic Heart Failure (clinicaltrials.gov) - May 19, 2014
P4, N=128, Recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Sep 2014 --> Apr 2015 Trial completion date: Sep 2014 --> Apr 2015
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment change, Metastases: Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 7, 2014
P1, N=50, Recruiting, Sponsor: PharmaMar
Trial completion date: Sep 2014 --> Apr 2015 N=40 --> 50
- | Aplidin (plitidepsin) / PharmaMar, Roche
New P1 trial, Combination therapy: Study of Plitidepsin (Aplidin (clinicaltrials.gov) - Mar 30, 2014
P1, N=25, Not yet recruiting, Sponsor: PharmaMar
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Combination therapy, Metastases: Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors (clinicaltrials.gov) - Mar 30, 2014
P1, N=60, Recruiting, Sponsor: PharmaMar
N=40 --> 50 Not yet recruiting --> Recruiting
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open: Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks (clinicaltrials.gov) - Nov 12, 2013
P1, N=42, Recruiting, Sponsor: PharmaMar
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors (clinicaltrials.gov) - Nov 7, 2013
P1, N=50, Not yet recruiting, Sponsor: PharmaMar
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors (clinicaltrials.gov) - Oct 24, 2013
P1, N=47, Completed, Sponsor: PharmaMar
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (clinicaltrials.gov) - Oct 24, 2013
P1, N=73, Recruiting, Sponsor: PharmaMar
- | Tuvero (fimasartan/rosuvastatin) / Boryung Group
Trial completion: To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin (clinicaltrials.gov) - Oct 19, 2013
P1, N=50, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Active, not recruiting --> Recruiting Recruiting --> Completed
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P2 trial, Combination therapy: A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Sep 24, 2013
P2, N=120, Not yet recruiting, Sponsor: PharmaMar
- | Tuvero (fimasartan/rosuvastatin) / Boryung Group
New P1 trial: To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin (clinicaltrials.gov) - Aug 12, 2013
P1, N=50, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
- Aplidin (plitidepsin) / PharmaMar, Roche
Trial termination, Metastases: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial (clinicaltrials.gov) - Jul 24, 2013
P2, N=24, Terminated, Sponsor: Institut Bergoni
Recruiting --> Completed Recruiting --> Terminated
- Aplidin (plitidepsin) / PharmaMar, Roche
Enrollment change, Metastases: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial (clinicaltrials.gov) - Jul 24, 2013
P2, N=24, Terminated, Sponsor: Institut Bergoni
Recruiting --> Terminated N=41 --> 24